Dyne Therapeutics, Inc. (DYN)
25.99
-0.11
(-0.42%)
USD |
NASDAQ |
Aug 24, 16:00
26.00
0.00 (0.00%)
After-Hours: 20:00
Dyne Therapeutics Debt to Equity Ratio : 0.3323 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.3323 |
| March 31, 2026 | 0.2022 |
| December 31, 2025 | 0.174 |
| September 30, 2025 | 0.1741 |
| June 30, 2025 | 0.2119 |
| March 31, 2025 | 0.0349 |
| December 31, 2024 | 0.0381 |
| September 30, 2024 | 0.0352 |
| June 30, 2024 | 0.0332 |
| March 31, 2024 | 0.0557 |
| December 31, 2023 | 0.3003 |
| September 30, 2023 | 0.1857 |
| June 30, 2023 | 0.1404 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.123 |
| December 31, 2022 | 0.1208 |
| September 30, 2022 | 0.1249 |
| June 30, 2022 | 0.1144 |
| March 31, 2022 | 0.0974 |
| December 31, 2021 | 0.0886 |
| September 30, 2021 | 0.0821 |
| June 30, 2021 | 0.0009 |
| March 31, 2021 | 0.0012 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.0271 |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Vor Biopharma, Inc. | -0.0144 |
| Neurocrine Biosciences, Inc. | 0.1088 |
| Recursion Pharmaceuticals, Inc. | 0.0728 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 994.01M |
| Total Liabilities (Quarterly) | 291.86M |
| Shareholders Equity (Quarterly) | 702.15M |
| Current Ratio | 12.02 |
| Net Debt Paydown Yield | -1.14% |